Kayla Vaden
Family · Huntsville, ALNPI 1225562747
Payments from drug & device makers
Across 269 payments — averaging $33.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$5K
- Novo Nordisk$1K
- AbbVie$749
- GSK$583
- AstraZeneca$500
- Braeburn Inc.$229
- plus $948 from 14 others
What the payments were for
- Speaking & faculty fees$2,93733%
- Travel & lodging$90110%
- Food & beverage$5,18057%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 22 | $4,546 |
| Novo Nordisk | 133 | $1,463 |
| AbbVie | 34 | $749 |
| GSK | 23 | $583 |
| AstraZeneca | 10 | $500 |
| Braeburn Inc. | 5 | $229 |
| Dexcom, Inc. | 7 | $226 |
| Bayer | 10 | $203 |
| Idorsia Pharmaceuticals US Inc | 4 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Lilly USA, LLC | 3 | $65 |
| Pfizer | 2 | $38 |
| Abbott | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Novartis | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Biocryst US Sales Co., LLC | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $15 |
| Exact Sciences | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,018 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $49,486 |
| RybelsusSemaglutide | 30 | $47,883 |
| FarxigaDapagliflozin Propanediol | 42 | $34,102 |
| JardianceEmpagliflozin | 22 | $31,211 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $29,250 |
| EliquisApixaban | 18 | $19,011 |
| MyrbetriqMirabegron | 16 | $14,078 |
| TrulicityDulaglutide | 12 | $13,560 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 94 | $13,319 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 56 | $2,077 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,065 |
| Colchicine | 18 | $1,628 |
| Omeprazole | 93 | $1,172 |
| Levothyroxine Sodium | 93 | $1,072 |
| Pravastatin Sodium | 66 | $941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,463 | $97,36976 claims |
| AstraZenecaFarxiga | $500 | $34,10242 claims |
| GSKTrelegy Ellipta | $583 | $29,25037 claims |
| PfizerEliquis | $38 | $19,01118 claims |
| Lilly USA, LLCTrulicity | $65 | $13,56012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Huntsville
- Leigh Ann ChildressHuntsville$240K
- Christina CanteyHuntsville$118K
- Julia BettsHuntsville$27K
- Joann IkardHuntsville$19K
- Hannah GarnettHuntsville$18K
- Alyssa FikesHuntsville$15K
- Justin WilsonCullman$1.1M
- Molly ReevesAuburn$158K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.